StockData
Structure Therapeutics Inc. logo

Structure Therapeutics Inc. (GPCR) stock

GPCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$18.17−0.40 (-2.15%)

Close on Nov 17, 2026Market cap $1.30BP/E –Yield –

Structure Therapeutics cash

Cash and short-term investments held at the end of each period.

Structure Therapeutics's cash was $1.34B at Jun 30, 2026. For fiscal 2025 it was $1.45B, up 63.7% from the year before. The highest annual figure on record is $1.45B in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.45B+63.7%
FY2024Dec 31, 2024$883.50M+89.1%
FY2023Dec 31, 2023$467.30M+414.4%
FY2022Dec 31, 2022$90.84M-13.7%
FY2021Dec 31, 2021$105.31M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.34B+70.7%
Q1 FY2026Mar 31, 2026$1.46B+74.3%
Q4 FY2025Dec 31, 2025$1.45B+63.7%
Q3 FY2025Sep 30, 2025$799.00M-12.7%
Q2 FY2025Jun 30, 2025$786.50M-15.2%
Q1 FY2025Mar 31, 2025$836.90M+91.8%
Q4 FY2024Dec 31, 2024$883.50M+89.1%
Q3 FY2024Sep 30, 2024$915.30M+345.6%
Q2 FY2024Jun 30, 2024$927.10M+312.8%
Q1 FY2024Mar 31, 2024$436.40M+81.2%
Q4 FY2023Dec 31, 2023$467.30M+414.4%
Q3 FY2023Sep 30, 2023$205.40M+631.2%
Q2 FY2023Jun 30, 2023$224.60M+304.8%
Q1 FY2023Mar 31, 2023$240.90M+375.9%
Q4 FY2022Dec 31, 2022$90.84M-13.7%
Q3 FY2022Sep 30, 2022$28.09M–
Q2 FY2022Jun 30, 2022$55.49M–
Q1 FY2022Mar 31, 2022$50.62M–
Q4 FY2021Dec 31, 2021$105.31M–

More Structure Therapeutics figures

See a number that looks wrong?